Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net income (loss)	$ 5,928,000	$ (14,909,000)
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	973,000	209,000
Amortization of intangible assets	1,394,000	104,000
Non cash lease expense	300,000	241,000
Stock-based compensation	2,258,000	1,349,000
Loss from equity method investment in SAVSU	0	448,000
Change in fair value of contingent consideration	(1,526,000)	0
Change in fair value of warrant liability	(5,472,000)	16,077,000
Other	0	2,000
Change in operating assets and liabilities
Accounts receivable, trade, net	924,000	(632,000)
Inventories	82,000	(1,341,000)
Prepaid expenses and other current assets	256,000	(32,000)
Accounts payable	63,000	(36,000)
Accrued compensation and other current liabilities	177,000	(348,000)
Other	(467,000)	(53,000)
Net cash provided by operating activities	4,890,000	1,079,000
Cash flows from investing activities
Payments related to the Astero Bio Acquisition, net of cash acquired	0	(12,439,000)
Purchase of property and equipment	(251,000)	(266,000)
Purchase of assets held for rent, net	(1,432,000)	0
Net cash used in investing activities	(1,683,000)	(12,705,000)
Cash flows from financing activities
Proceeds from PPP Loan	2,175,000	0
Payoff of PPP Loan	(2,175,000)	0
Payments of contingent consideration	(483,000)	0
Proceeds from sale of common stock, net of fees	19,914,000	0
Proceeds from exercise of common stock options	783,000	462,000
Proceeds from exercise of warrants	24,000	138,000
Other	(14,000)	(14,000)
Net cash provided by financing activities	20,224,000	586,000
Net increase (decrease) in cash and cash equivalents	23,431,000	(11,040,000)
Cash and cash equivalents - beginning of period	6,448,000	30,657,000
Cash and cash equivalents - end of period	29,879,000	19,617,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassed from warrant liability to common stock	33,111,000	0
Reclassification of warrant liability to equity upon exercise	57,000	400,000
Purchase of property & equipment not yet paid	29,000	4,000
Purchase of equipment with debt	133,000	0
Deferred financing costs not yet paid	55,000	0
Stock issued as bonus consideration	$ 314,000	$ 0